Phase I clinical studies have shown that 99mTc-labeled ADAPT6 [21] and DARPin G3 [22] provide discrimination between HER2-positive and HER2-negative breast cancer tumors and are potential candidates for further clinical development. The gene discussed is ERBB2; the disease is breast cancer.